Search Results

You are looking at 1 - 10 of 78 items for :

  • polycystic ovarian syndrome x
  • Refine by Access: All content x
Clear All
Open access

Ladan Younesi, Zeinab Safarpour Lima, Azadeh Akbari Sene, Zahra Hosseini Jebelli, and Ghazaleh Amjad

Introduction Polycystic ovarian syndrome (PCOS) is one of the most common endocrinopathies in humans, which affects five to ten percent of women in childbearing age ( 1 ). About 20 to 30 percent of women in reproductive age show polycystic

Open access

Gunjan Garg, Garima Kachhawa, Rekha Ramot, Rajesh Khadgawat, Nikhil Tandon, V Sreenivas, Alka Kriplani, and N Gupta

(OH)D level further inhibit the application of vitamin D intervention trials. Polycystic ovarian syndrome (PCOS) is now recognized as one of the most common endocrinopathies in women of reproductive age with a prevalence of 4–10% (9) . Women with PCOS

Open access

Liza Haqq, James McFarlane, Gudrun Dieberg, and Neil Smart

Introduction Polycystic ovarian syndrome (PCOS) is a heterogeneous endocrine disorder, affecting 18–22% of reproductive-age women (1) . PCOS was first reported in 1935 by Stein & Leventhal (2) and is characterised by clinical or biochemical

Open access

Line K Johnson, Kirsten B Holven, Njord Nordstrand, Jan R Mellembakken, Tom Tanbo, and Jøran Hjelmesæth

Introduction Women with polycystic ovarian syndrome (PCOS) are often overweight and have a central fat distribution (1) . It is well known that abdominal obesity is associated with insulin resistance, metabolic syndrome (MS) and increased risk of

Open access

Rosalie Cabry, Philippe Merviel, Aicha Madkour, Elodie Lefranc, Florence Scheffler, Rachel Desailloud, Véronique Bach, and Moncef Benkhalifa

use (especially in an occupational setting) on female reproductive capacity and certain female infertility diseases, such as premature ovarian failure (POF), polycystic ovarian syndrome (PCOS), and endometriosis. Furthermore, pesticide exposure might

Open access

Angela Köninger, Philippos Edimiris, Laura Koch, Antje Enekwe, Claudia Lamina, Sabine Kasimir-Bauer, Rainer Kimmig, and Hans Dieplinger

.3275/7682 ). 8 Baillargeon JP Nestler JE . Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? Journal of Clinical Endocrinology and Metabolism 2006 91 22 – 24 . ( doi:10.1210/jc.2005-1804 ). 9 Dunaif A Segal

Open access

Mojca Jensterle, Nika Aleksandra Kravos, Simona Ferjan, Katja Goricar, Vita Dolzan, and Andrej Janez

Introduction Polycystic ovarian syndrome (PCOS) brings significant heterogeneity of cardio-metabolic risk at the time of the confirmed diagnosis ( 1 ). Obesity, menstrual irregularity and hyperandrogenism are recognized as the most important

Open access

Thomas Reinehr, Alexandra Kulle, Juliane Rothermel, Caroline Knop-Schmenn, Nina Lass, Christina Bosse, and Paul-Martin Holterhus

Introduction Polycystic ovarian syndrome (PCOS) is a heterogeneous syndrome that is characterized by features of anovulation (amenorrhea and oligomenorrhea) combined with symptoms of androgen excess (hirsutism, acne and alopecia) ( 1 ). The

Open access

Milène Tetsi Nomigni, Sophie Ouzounian, Alice Benoit, Jacqueline Vadrot, Frédérique Tissier, Sylvie Renouf, Hervé Lefebvre, Sophie Christin-Maitre, and Estelle Louiset

. Polycystic ovary syndrome (PCOS) is the most common cause of hyperandrogenism (1, 2, 3) . According to the Rotterdam criteria, diagnosis of PCOS is determined on the basis of chronic anovulation, polycystic ovaries, clinical and/or biochemical evidence of

Open access

Xiying Zeng, Yinxiang Huang, Mulin Zhang, Chen Yun, Ye Jiawen, Yan Han, Ma Danyan, Xin Zheng, Xiaohong Yan, and Changqin Liu

Objective: Anti-Müllerian hormone (AMH) is recognized as the most important biomarker for ovarian reserve. In this cross-sectional study, we aimed to explore the potential association of AMH with central obesity or general obesity in women with polycystic ovary syndrome (PCOS).

Methods: In this cross-sectional study, 179 patients with PCOS were enrolled and underwent anthropometric measurements (BMI and waist circumference (WC)) and serum AMH level detection. Pearson's correlation and multivariable logistic regression analyses were performed to determine associations of AMH with central obesity and general obesity.

Results: Subjects with the increasing of body mass index (BMI) showed significantly lower values of AMH (median (IQR) 8.95 (6.03-13.60) ng/mL in normal weight group, 6.57 (4.18-8.77) ng/mL in overweight group, and 6.03 (4.34-9.44) ng/mL in obesity group, respectively, p=0.001), but higher levels of systolic blood pressure, fasting insulin, total cholesterol, triglycerides, low-density lipoprotein cholesterol, and obesity indices (WC, hip circumferences, waist-to-hip ratio (WHR), waist-to-height ratio (WHtR) and Chinese visceral adiposity index (CVAI)) respectively. Compared with the group of PCOS women without central obesity, the group with central obesity had significantly lower value of AMH (median (IQR) 8.56(5.29-12.96) vs. 6.22(4.33-8.82) ng/mL; p=0.003). Pearson’s correlation analysis showed that AMH were significantly and negatively correlated with BMI (r=-0.280; p<0.001), WC (r=-0.263; p<0.001), WHtR (r=-0.273; p<0.001), and CVAI (r=-0.211; p=0.006) respectively. Multivariate logistic regression analysis with adjustment for potential confounding factors showed that AMH was independently and negatively associated with central obesity, but was not significantly associated with general obesity.

Conclusions: AMH was independently and negatively associated with central obesity. Closely monitoring WC and AMH should be addressed in terms of assessing ovarian reserve in women with PCOS.